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Contrast-enhanced computed tomography (CECT) 
acquisition facilitates an accurate delineation of tar-
get volumes in hepatocellular carcinoma (HCC) 
[1], whereas an alternation in the hounsfield unit 
(HU) value due to contrast media will result in 
erroneous dose calculation [2]. This might result 
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background: a purpose of the study was to investigate the dosimetric impact of contrast media on dose calculation using 
average 4D contrast-enhanced computed tomography (4D-cecT) and delayed 4D-cT (d4D-cT) images caused by cT simula-
tion contrast agents for stereotactic body radiation therapy (sBrT) of liver cases.
Materials and methods: Fifteen patients of liver sBrT treated using the volumetric modulated arc therapy (VMaT) technique 
were selected retrospectively. 4D-cecT, and d4D-cT were acquired with the anzai gating system and Ge cT. For all patients, 
gross target volume (GTV) was contoured on the ten phases after rigid registration of both the contrast and delayed scans 
and merged to generate internal target volume (ITV) on average cT images. region of interest (rOI) was drawn on contrast 
images and then copied to the delayed images after rigid registration of two average cT datasets. The treatment plans were 
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in overestimation or underestimation of the dose 
and unintended dose is delivered to the target and 
healthy tissues. Most of the authors have studied 
the dosimetric influence of contrast media in radio-
therapy planning on three dimensional computed 
tomography (3D-CT) image datasets for various 
clinical sites [3–9]. Many authors have reported 
clinically insignificant effects, whereas few authors 
have suggested incorporating the effect of contrast 
media by assigning HU values to the contrast-en-
hanced structures or using non-contrast CT datas-
ets for treatment planning.
Most commonly, triphasic 3D-CT scans along 
with a non-contrast four-dimensional computed 
tomography (4D-CT) are acquired for target de-
lineation and planning for patients with HCC. 
This method is accessible to patients who cannot 
co-operate with the breath-hold technique. The 
triphasic CT takes advantage of HCC’s character-
istic enhancement in the arterial phase, followed 
by a washout in the portal or delayed phases [10]. 
Internal target volume (ITV) is assessed using 
4D-CT and an isotropic or anisotropic margin is 
added around the clinical target volume (CTV) 
based upon the target movement. However, there 
are limitations to this method; the 3D-CT may 
be acquired at any random phase, giving an ITV 
margin on a random phase will result in over 
treatment of the healthy tissues. Also, the 4D-CT 
derived geometric expansion may not cover the 
hysteresis of the liver. To tackle these problems, 
our department utilizes a synchronized intrave-
nous contrast 4D planning CT (4D-CECT) fol-
lowed by a delayed 4D planning CT (d4D-CT) 
[11–13]. This method allows for precise target de-
lineation on a 4D-CT and dose calculation on the 
average phase of the 4D-CT. Synchronized 4D-CT 
contrast scans also avoid the need for triple-phase 
CT scans for target delineation, reducing the ra-
diation exposure to the patient [11, 12]. Also, the 
day to day matching on a 4D cone beam computed 
tomography (CBCT) may be more accurate with 
the average phase of 4D-CT.
Earlier studies have quantified the effect of con-
trast media on dose distribution using 3D-CT im-
age data sets. To the best of our knowledge, no 
study has assessed the impact of contrast media on 
dose calculation on a 4D-CECT. As contrast media 
can widely alter the dose distribution in the healthy 
liver, its dosimetric impact needs to be studied.
The present study aims to study the dosimetric 
impact of contrast media on dose calculation using 
average 4D-CECT and d4D-CT images caused by 
CT simulation contrast agents.
Materials and methods
The present study analyzes the dosimetric impact 
of contrast 4D-CT on the accuracy of dose dis-
tribution. Fifteen patients of HCC were randomly 
selected for this retrospective study with the char-
acteristics as shown in Table 1. The details of the 
steps involved in the study are given in subsequent 
sections:
cT scan acquisition
All the patients were positioned with Blue-
BAG™ (Elekta AB, Stockholm, Sweden) in a su-
pine position. After ensuring normal renal func-
tion, 18 G to 20 G three-way IV cannula was 
inserted in the antecubital vein to ensure an ad-
equate flow of contrast. The CT scans were ac-
quired as per protocol approved by the depart-
ment for routine clinical practice. All patients 
underwent 4D-CECT, and d4D-CT using 64-slice 
optima GE CT equipment (GE Medical Systems, 
USA) integrated with GE Discovery 710 Time of 
Flight (TOF) PET-CT scanner (GE Healthcare, 
Amersham, UK). A pressure sensor-based load 
cell device of the Anzai gating system (AZ-733V; 
Anzai Medical System, Tokyo, Japan) using an 
elastic belt wrapped around the patient’s abdo-
men to measure the respiratory waveform. The 
load cell was placed below the diaphragm level on 
the right side of the abdomen.
An automatic contrast injector Ulrich CT mo-
tion contrast injector (Ulrich medical® interface, 
Ulrich GmbH & Co. KG, Germany) was connected 
to the IV line, and 125 ml of VisipaqueTM (iodixanol) 
containing 270 mg of iodine per ml was injected at 
a rate of 3ml/second. 4DCT was acquired from the 
carina to 6cm below the inferior-most point of the 
liver. A 140 kVp (tube potential), 140–160 mA (tube 
current), 0.5–1 sec/rotation speed, and a constant 
detector coverage of 2 cm (detector coverage is the 
length scanned by the CT scanner for a duration 
equal to the patient’s cine time) was applied. A de-
layed 4D-CT scan was taken after a gap of 5 min-
utes. The CT scans were acquired with 2.5mm slice 
thickness and eight images/rotation [11]. 
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contour delineation
For each patient, contrast and delayed 4D-CT 
scans were acquired. The 4D-CT datasets were 
imported into a treatment planning system (TPS; 
Monaco ver. 5.1, Elekta CMS, Maryland Heights, 
MO, USA), and the average CT dataset was gener-
ated in TPS. For all patients, gross tumor volume 
(GTV) was contoured on the ten phases after rigid 
registration of both the contrast and delayed scans. 
Areas that showed contrast enhancement and de-
layed washout were contoured as GTV and were 
merged to generate ITV on average CT images. For 
treatment planning, planning target volume (PTV) 
was generated by giving a population-specific 5 
mm uniform margin around ITV to incorporate 
the set-up uncertainties. The GTV, CTV, and PTV, 
along with the other organs at risk (OAR), were 
delineated as mentioned in RTOG 1112 protocol14. 
ROI was drawn on contrast images and then copied 
to the delayed images after rigid registration of two 
average CT datasets. The same method was em-
ployed to analyze different CT datasets.
Treatment planning
All the treatment plans were generated on aver-
age CT images using Monaco TPS for delivery with 
Versa HD (Elekta, Stockholm, Sweden) equipped 
with Agility MLC 80 leaf pairs for volumetric mod-
ulated arc therapy (VMAT) with a maximum dose 
rate of 600 MU/min using 6MV photon energy. 
Segment shape optimization (SSO) was used for 
the optimization of VMAT plans with minimum 
segment width of 0.5 cm and medium fluence 
smoothing followed by final dose calculation using 
the Monte Carlo dose calculation algorithm with 
2 mm grid size and 3% Monte Carlo. The treatment 
planning was done with a very tight margin of 
0–1 mm around the target using auto jaw tracking. 
All patients were planned with the VMAT tech-
nique (previous work has suggested that VMAT 
is superior to modified dynamic conformal arc) 
using two partial arcs (60–180 degrees) for a pre-
scription dose in the range of 7–10 Gy/fraction us-
ing optimized planning parameters recommended 
by Thaper et al. [15–17]. Complementary collima-
tor angles of 30 degrees and 330 degrees were used 
to reduce the tongue and groove effect, and accu-
mulative effects of transmission through multileaf 
collimator (MLC). The dose-volume constraints of 
PTV and OAR, as mentioned in RTOG 1112, were 
achieved [14].
analysis of treatment plans
Three types of treatment plans were generated, 
as mentioned in Table 2. The treatment plans were 
optimized on arterial average CT (Dart-reopt), delayed 
average CT (Ddel-reopt), arterial average CT with an 
electron density of heart override (Dhart-reopt). Dhart-reopt 
table 1. patient characteristics along with planning target volume
BCLC staging TNM/AJCC staging CP score PTV [cc] Age [yrs]/Gender
patient 1 c T4N0M0 a5 772 52/M
patient 2 c T4N0M0 a6 213 48/M
patient 3 c T4N0M0 a5 896 67/M
patient 4 c T4N1M0 a6 477 56/M
patient 5 c T3N1M1 a6 306 74/M
patient 6 c T4N0M0 a5 176 65/M
patient 7 c T4N0M0 a6 241 55/M
patient 8 c T4N0M0 a5 898 59/F
patient 9 c T4N0M0 a6 151 57/M
patient 10 c T4N0M0 a6 313 64/F
patient 11 c T4N0M0 a5 118 49/M
patient 12 c T4N1M0 a6 513 65/M
patient 13 c T4N0M0 a6 663 50/F
patient 14 B T2N0M0 a6 89 69/F
patient 15 c T4N0M0 a5 159 52/M
BcLc — Barcelona clinic liver cancer; aJcc — american Joint committee on cancer; cp score — child pugh score; pTV — planning target volume
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was evaluated as HU value of the heart is signifi-
cantly higher in a contrast-enhanced phase and can 
cause uncertainties in dose calculations, especially 
if the tumor is located near the upper dome of the 
diaphragm. The beam characteristics and optimi-
zation parameters of the radiotherapy plan gener-
ated in one CT data set were copied and applied 
to the other CT datasets. All statistical analyses 
were performed using SPSS for Windows (Version 
20.0 IBM Corporation, Armonk, NY). The mean 
and standard deviations of the plan parameters and 
OAR doses were calculated for each group. Degree 
of modulation (DoM), total control points (CP), 
mean HU of the liver and aorta, average segment 
area (SA), total monitor units (MU), mean liver 
dose (MLD), mean kidney dose, mean spleen dose, 
0.5cc of the esophagus, duodenum, stomach, small 
bowel, large bowel, spinal cord and dose to 30cc for 
the heart was evaluated. One way ANOVA was per-
formed using the tukey s-b method with p > 0.05 as 
a meaningless level of statistical tests.
results
Figure 1 represents a typical axial tomographic 
slice of average arterial and delayed CT’s recon-
structed from the 4D-CT dataset of a single patient. 
Enhancement in the average arterial phase is visible 
in the aorta and liver of the axial slice. Also, the 
mean HU value is 100 and 82 in average contrast 
table 2. Quantitative analysis of organ at risk (Oar) doses (mean, standard deviation and p-value)
Dart-reopt Dhart-reopt Ddel-reopt p-value
MLD 15.95±4.38 15.91±4.33 15.77±4.9 0.992
rK (Mean) 6.24±5.78 6.16±5.81 5.82±5.16 1.000
eso (0.5 cc) 15.86±6.71 16.55±6.63 15.68±6.41 0.989
Duo (0.5 cc) 20.07±14.11 20.28±14.19 18.44±13.44 0.998
sto (0.5 cc) 20.55±8.86 20.29±8.83 19.76±8.72 0.969
heart (30 cc) 11.28±7.30 11.11±7.07 11.15±6.90 0.975
sB (0.5 cc) 16.26±13.86 15.62±13.89 15.9±14.66 0.998
LB (0.5 cc) 23.52±13.73 23.47±13.71 23.25±13.92 1.000
cord (0.5 cc) 13.05±5.84 13.08±5.88 12.64±5.37 1.000
spleen (Mean) 3.12±1.64 3.37±1.76 3.39±1.82 0.947
MLD — mean liver dose; rK — right kidney; eso — esophagus; Duo — duodenum; sto — stomach; sB — small bowel; LB — large bowel
Figure 1. Typical axial slice of computed tomography (cT) dataset of average arterial phase and average delayed phase 
for a typical patient
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and average delayed CT image for a particular VOI, 
respectively. 
Table 3 summarizes the quantitative analysis of 
the mean HU value of the liver and aorta, MU, CP, 
DoM and SA of the treatment plan averaged over 
all the patients. The variation in HU value of the 
aorta in Dart-reopt is significantly different from Ddel-reopt 
(p < 0.005). However, the other parameters evalu-
ated in Table 2 showed statistically insignificant 
variation (p > 0.05). 
Figure 2 represents the scatter plot of the nor-
malized HU and MU values w.r.t corresponding to 
the values in the delayed phase. A positive correla-
tion was observed; however, it was non-significant 
(p > 0.05). 
Figure 3 represents the percentage variation of 
Dart-reopt and Dhart-reopt in MU, CP, SA w.r.t. to Ddel-reopt. 
Average segment area is higher for both Dart-reopt 
(1.31%) and Dhart-reopt (3.42%) in comparison to 
Ddel-reopt, though the difference was non-significant 
(p > 0.05, Tab. 2). Similarly, the mean variation in 
MU was found to be –1.30% and -3.39% for Dart-reopt 
and Dhart-reopt, respectively, w.r.t. Ddel-reopt (p > 0.05, 
Tab. 2). The total control points were 4.28% higher 
in Dart-reopt and almost similar in Dhart-reopt (–0.33%) 
w.r.t. Ddel-reopt with p-value being greater than 0.05 
(Tab. 2). 
Table 3 summarizes the quantitative analysis of 
OAR doses of the treatment plan corresponding 
to treatment plans calculated on three arms of the 
study. The dose-volume parameters evaluated are 
according to the RTOG 1112 protocol. All the OAR 
evaluated has shown statistically insignificant varia-
tion (p > 0.05, Tab. 3) using one way ANOVA analy-
sis. PTV doses were normalized to the same value 
for all the plans.
table 3. Quantitative analysis of plan parameters averaged over all the patients (mean and standard deviation) along 
with the statistical significance
Dart-reopt Dhart-reopt Ddel-reopt p-value
MU 3784.52 ± 780.46 3720.00 ± 808.12 3874.197 ± 887.03 0.885
hU (liver) 89.64 ± 21.42 89.64 ± 21.42 81.00 ± 7.86 0.354
hU (aorta) 281.57 ± 96.50 281.57 ± 96.50 90.64 ± 11.88 < 0.005
cp 248.79 ± 54.73 236.71 ± 47.88 237.28 ± 42.74 0.762
DoM 4.93 ± 1.03 4.85 ± 1.02 5.02 ± 1.02 0.900
sa 17.63 ± 7.53 18.13 ± 7.93 17.45 ± 7.11 0.970
MU — monitor units; hU — hounsfield unit; cp — control points; DoM — degree of modulation; sa — segment area 
Figure 2. scatter plot of normalized monitor units (MU) 
versus normalized hounsfield units (hU) of the dose 





















Figure 3. percentage variation of Dart-reopt and Dhart-reopt in 
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Discussion
The effect of IV contrast agent on dose calcu-
lations has been studied by several authors using 
3D-CT images. Xiao et al. reported a non-signifi-
cant difference in dosimetric parameters for treat-
ment planning on hepatic arterial phase, porto-ve-
nous phase, and non-contrast CT [18]. Sahbaee et 
al. reported a 35% increase in the dose of the liver 
for specific contrast media injection protocol [19]. 
Shibamoto et al. also suggested that contrast media 
have an impact on dose distribution for upper-ab-
dominal irradiation especially when beams pass 
through the liver, spleen, or kidneys [20]. None of 
the authors studied the dosimetric comparison of 
treatment planning on 4D-CECT and d4D-CT im-
ages in liver cases.
In this study, the effect of the IV contrast agent 
on dose calculations on average 4D-CT images in 
radiation treatment planning was evaluated. For the 
purpose, the two sets of CTs (average contrast and 
average non-contrast) were taken in the same posi-
tion and setting of scan acquisition parameters. As 
the 4D-CT acquisition takes a comparatively longer 
time as compared to conventional 3D-CT, the en-
hancement on average CT may be different from 
contrast 3D-CT. Hence, the evaluation of its effect 
on dose calculation was necessary as the treatment 
planning process makes use of HU values of CT 
images to calculate the dose which is altered with 
the use of IV contrast. 
Considering Ddel-reopt as the reference, the param-
eters can be compared with the doses achieved from 
doses calculated at other CT datasets. The treatment 
planning on Dart-reopt and Dhart-reopt resulted in –1.30% 
and –3.39% average change in MU, respectively, w.r.t 
Ddel-reopt. However, it is to be noted that the difference 
was statistically non-significant (p > 0.05) (Tab. 2). 
These findings are consistent with the findings of 
Xiao et al. which found that there is a non-significant 
difference in dosimetric parameters (MU) for plan-
ning on arterial, porto-venous, and non-contrast 
CT images. However, the study of Xiao et al. was 
performed for 3D images only and had an inherent 
limitation of image acquisition at any random phase 
of the respiratory cycle which may alter the position 
of tumor and OARs in different CT datasets owing 
to uncertainty in results quoted.
Further, Ramm et al. reported that an increase 
in the number of incident beams lessens the ef-
fect of contrast on dose calculation [2]. As VMAT 
includes a large number of incident beams, the 
change in MU between doses of different CT da-
tasets is minimal. Mean HU values of the liver 
were found to be 8.64 units higher for Dart-reopt 
than Ddel-reopt. It is also to be emphasized that mean 
variation in HU values of the liver in arterial 
and delayed CT datasets is also non-significant, 
however, value is lower as compared to the value 
of other parameters (p = 0.354, Tab. 2).  The ob-
servations are in contrast to the results reported 
by Shibamoto et al. which quoted an increase of 
51 ± 17 HU of enhanced liver CT over non-en-
hanced. It can be attributed to the use of a small 
cohort of patients and variability in the enhance-
ment of HCC. Also, ten phases of CT scan are ac-
quired according to cine time and respiratory rate 
(generally in the order of ~ 4–5 sec), generating 
an average CT results in averaging of HU values 
of all ten phases which might result in a lower HU 
value than the expected value of the liver in the 
arterial phase. Further, the HU value of the aorta 
at an axial slice of the upper border of the liver 
was evaluated and a significant difference was 
observed (p < 0.05, Tab. 2).
We also analyzed the dosimetric parameters of 
the critical organs as mentioned in the RTOG 1112 
protocol. Three arms were compared as shown in 
table 3 and the difference in all the critical organs 
doses was statistically non-significant (p > 0.05). 
One of the limitations of the study is that the small 
cohorts of patients are used in this study. Another 
limitation is that only rigid registration is consid-
ered while registering two average CTs, however, 
deformable image registration may give more accu-
rate results as there may be a residual shift between 
OAR due to a little bit change in the respiratory 
pattern of the patient. 
conclusion
SBRT is a challenging treatment modality for 
moving tumors, especially where the liver deforms 
continuously during treatment. Contrast enhanced 
4D-CT is advantageous in accurate delineation of 
tumors and assessing accurate ITV. The treatment 
plans generated on average 4D-CECT and average 
d4D-CT has a clinically insignificant effect on dosi-
metric parameters. In our opinion, dose calculation 
can be performed on contrast-enhanced average 
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CT images while overriding the electron densities 
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